{
  "name": "Quercetin + Dasatinib",
  "category": "protocol",
  "mechanisms": [
    "Senolytic — clears senescent cells",
    "Anti-inflammatory"
  ],
  "evidenceGrade": "C",
  "riskProfile": "medium",
  "dosage": {
    "standard": "D:100mg + Q:1000mg, 3 days/month",
    "range": "Various protocols",
    "notes": "Intermittent dosing only. Dasatinib requires prescription."
  },
  "keyFindings": [
    "First senolytic combination shown to clear senescent cells in humans",
    "Improved physical function in IPF patients",
    "Hit-and-run approach — cells cleared but drugs not continuously needed"
  ],
  "tags": [
    "senolytic",
    "senescent-cells",
    "protocol",
    "intermittent"
  ],
  "id": "prod-quercetin-dasatinib",
  "description": "First senolytic combination shown to clear senescent cells in humans",
  "interactions": [],
  "sideEffects": [],
  "contraindications": [],
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T08:33:44.508Z",
  "createdAt": "2026-02-04T08:33:44.508Z"
}